Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;13(2):e12404.
doi: 10.1002/jev2.12404.

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Joshua A Welsh  1 Deborah C I Goberdhan  2 Lorraine O'Driscoll  3   4   5 Edit I Buzas  6   7   8 Cherie Blenkiron  9 Benedetta Bussolati  10 Houjian Cai  11 Dolores Di Vizio  12 Tom A P Driedonks  13 Uta Erdbrügger  14 Juan M Falcon-Perez  15   16   17 Qing-Ling Fu  18   19 Andrew F Hill  20 Metka Lenassi  21 Sai Kiang Lim  22   23   24 Mỹ G Mahoney  25 Sujata Mohanty  26 Andreas Möller  27   28 Rienk Nieuwland  29   30 Takahiro Ochiya  31 Susmita Sahoo  32 Ana C Torrecilhas  33 Lei Zheng  34 Andries Zijlstra  35   36 Sarah Abuelreich  37 Reem Bagabas  37 Paolo Bergese  38   39   40 Esther M Bridges  41 Marco Brucale  42   43 Dylan Burger  44   45   46 Randy P Carney  47 Emanuele Cocucci  48   49 Rossella Crescitelli  50   51 Edveena Hanser  52   53 Adrian L Harris  54 Norman J Haughey  55 An Hendrix  56   57 Alexander R Ivanov  58 Tijana Jovanovic-Talisman  59 Nicole A Kruh-Garcia  60 Vroniqa Ku'ulei-Lyn Faustino  37 Diego Kyburz  53   61 Cecilia Lässer  62 Kathleen M Lennon  37 Jan Lötvall  63 Adam L Maddox  37 Elena S Martens-Uzunova  64 Rachel R Mizenko  47 Lauren A Newman  65 Andrea Ridolfi  66 Eva Rohde  67   68   69 Tatu Rojalin  47   70 Andrew Rowland  65 Andras Saftics  37 Ursula S Sandau  71 Julie A Saugstad  71 Faezeh Shekari  72   73 Simon Swift  74 Dmitry Ter-Ovanesyan  75 Juan P Tosar  76   77 Zivile Useckaite  65 Francesco Valle  42   43 Zoltan Varga  78   79 Edwin van der Pol  30   80   81 Martijn J C van Herwijnen  82 Marca H M Wauben  82 Ann M Wehman  83 Sarah Williams  84 Andrea Zendrini  38   39 Alan J Zimmerman  58 MISEV ConsortiumClotilde Théry  85   86 Kenneth W Witwer  87   88   89
Collaborators, Affiliations

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Joshua A Welsh et al. J Extracell Vesicles. 2024 Feb.

Erratum in

Abstract

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its 'Minimal Information for Studies of Extracellular Vesicles', which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.

Keywords: MISEV; ectosomes; exosomes; extracellular particles; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardisation.

PubMed Disclaimer

Conflict of interest statement

Pierre Arsène is CEO of Mursla Ltd. and Chair of Exosla Ltd; Antonella Bongiovanni has filed the patent (PCT/EP2020/086622) related to microalgal‐derived extracellular vesicles and is co‐founder and CEO of the spin‐off company EVEBiofactory srl; Paul C Boutros sits on the scientific advisory boards of Sage Bionetworks, Intersect Diagnostics Inc and BioSymetrics Inc; Xandra O Breakefield is Scientific Advisor for Evox and MGB‐Cannon; Edit I Buzas is a member of the Scientific Advisory Boards of Sphere Gene Therapeutics Inc (Boston, MA, USA) and ReNeuron (UK); David RF Carter is an Evox Therapeutics Ltd, employee and stock option holder; Anna Cifuentes‐Rius was employed by Exopharm Ltd when the survey was conducted ACR is a shareholder of Exopharm Ltd; Rossella Crescitelli has developed multiple EV‐associated patents for putative clinical utilisation and they own equity in Exocure Sweden AB; Andrew Devitt is Chief Technical Officer, co‐founder, and director of EVolution Therapeutics; Erez Eitan works and has equity in NeuroDex, a company that develops EV‐based diagnostics; Samir EL Andaloussi is co‐founder of Evox Therapeutics; Ludwig Ermann Lundberg is an employee of BioGaia; Susanne Gabrielsson has a patent on B cell derived EVs in immune therapy and is part of the Scientific Advisory Board of Anjarium Biosciences; Ernesto Gargiulo is a medical writer at Novo Nordisk A/S; Bernd Giebel is a member of the Scientific Advisory Boards of Mursla Ltd, ReNeuron, and PLBioscience and is the founding director of Exosla Ltd; André Görgens is a consultant for and has equity interest in Evox Therapeutics (Oxford, UK) and is an inventor on several patent applications and patents related to EV isolation, modification, and analytics; Ahmed GE Ibrahim owns stock in Capricor Therapeutics; Marzena Kurzawa‐Akanbi Kurzawa‐Akanbi is an academic founder and Chief Scientific Officer at ESP Diagnostics Limited; Quentin Lubart is an employee of Abbelight (Cachan, France), which constructs and sells super‐resolution microscopes to characterize EVs; Fabrice Lucien receives consulting fees from Mursla Bio and Early is Good; Elisa Lázaro‐Ibáñez is employed by AstraZeneca R&D; Jan Lötvall is co‐founder of two companies aiming to develop EV‐based therapeutics, Exocure Sweden AB and Nexo Therapeutics AB, has been or is a scientific consultant for NanoSight, Clara Biotech and ExoCoBio, and was Editor‐in‐Chief of the Journal of Extracellular Vesicles during the development and publication of MISEV2023; Eduardo Marbán has founder's equity in Capricor Therapeutics Inc; Maurizio Muraca is a consultant for EXO Biologics (Liège, Belgium); Irina Nazarenko is a scientific adviser of CapCO Bio GmbH; D Michiel Pegtel has research funding from Takeda, Amgen, Abbvie, and Gilead, is an advisor of Y2Y BV, and has equity in Y2Y BV; Janusz Rak is inventor on a patent on oncogene‐carrying EVs that is licensed to NXPharmaGene; Gregory E Rice is Chief Scientific Officer, Inoviq Ltd; Andrew Rowland is a recipient of investigator‐initiated research funding outside of the scope of this publication from AstraZeneca, Boehringer Ingelheim, and Pfizer and is a recipient of speakers fees from Boehringer Ingelheim and Genentech; Susmita Sahoo performs research funded by Evox Therapeutics; Randy Schekman is a member of the Scientific Advisory Boards of companies involved in the analysis and diagnostic/therapeutic application of various forms of synthetic or native extracellular vesicles in diagnostics: Sail (formerly Senda) Biomedicines, Invaio Sciences, Mercy BioAnalytics, and Esperovax; Raymond M Schiffelers is CSO of Excytex bv; Johan Skog is an employee of Bio‐Techne and an inventor on patents for exosome isolation and analysis; Vera A Tang is a consultant for Beckman Coulter on small particle flow cytometry; Clotilde Théry is an inventor on a submitted patent on therapeutic use of EVs; Edwin van der Pol is cofounder and shareholder of Exometry, Amsterdam, The Netherlands; Joshua A Welsh is an inventor on patents and patent applications related to EV analysis; Oscar PB Wiklander has stock options with Evox Therapeutics; Kenneth W Witwer is or has been an advisory board member of ShiftBio, Exopharm, NeuroDex, NovaDip, and ReNeuron; holds NeuroDex options; privately consults as Kenneth Witwer Consulting; and conducts research under a sponsored research agreement with Ionis Pharmaceuticals.

Figures

FIGURE 1
FIGURE 1
Hierarchy of EP nomenclature. Extracellular particles include vesicular and non‐vesicular particles. This figure presents several distinctions that can be made between classes of EPs, as well as examples of possible nomenclature. EP: extracellular particle; EV: extracellular vesicle; SV: synthetic vesicle; ACDV: artificial cell‐derived vesicle; NVEP: non‐vesicular extracellular particle. See also Section 2 and Table 2.
FIGURE 2
FIGURE 2
Position of some EV separation and concentration methods on a recovery (yield) versus specificity grid. Dashed blue arrows indicate combinations of methods resulting in increased specificity. Specificity can be of different types: Size exclusion chromatography (SEC) separates EVs by size from many (but not all) NVEPs, but all EV types are recovered together, while differential ultracentrifugation (dUC) separates EV subtypes based on their size/weight, but also co‐isolates NVEPs at high speeds. Note that many ‘exosome purification’ kits use precipitation (P), thus do not isolate pure exosomes or even EVs but a mixture of EPs, while some use affinity precipitation (AP), which may be more specific to EVs but not exosomes. Those who develop new methods should consider positioning their EV outcomes on such a graph.

References

    1. Aalberts, M. , van Dissel‐Emiliani, F. M. , van Adrichem, N. P. , van Wijnen, M. , Wauben, M. H. , Stout, T. A. , & Stoorvogel, W. (2012). Identification of distinct populations of prostasomes that differentially express prostate stem cell antigen, annexin A1, and GLIPR2 in humans. Biology of Reproduction, 86, 82. - PubMed
    1. Aasebø, E. , Opsahl, J. A. , Bjørlykke, Y. , Myhr, K. M. , Kroksveen, A. C. , & Berven, F. S. (2014). Effects of blood contamination and the rostro‐caudal gradient on the human cerebrospinal fluid proteome. PLoS ONE, 9, e90429. - PMC - PubMed
    1. Abbatiello, S. E. , Mani, D. R. , Schilling, B. , Maclean, B. , Zimmerman, L. J. , Feng, X. , Cusack, M. P. , Sedransk, N. , Hall, S. C. , Addona, T. , Allen, S. , Dodder, N. G. , Ghosh, M. , Held, J. M. , Hedrick, V. , Inerowicz, H. D. , Jackson, A. , Keshishian, H. , Kim, J. W. , … Carr, S. A. (2013). Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography‐multiple reaction monitoring‐MS (LC‐MRM‐MS). Molecular & Cellular Proteomics, 12, 2623–2639. - PMC - PubMed
    1. Aebersold, R. , & Mann, M. (2003). Mass spectrometry‐based proteomics. Nature, 422, 198–207. - PubMed
    1. Aguet, F. , Antonescu, C. N. , Mettlen, M. , Schmid, S. L. , & Danuser, G. (2013). Advances in analysis of low signal‐to‐noise images link dynamin and AP2 to the functions of an endocytic checkpoint. Developmental Cell, 26, 279–291. - PMC - PubMed

Grants and funding